Vivan Developed Therapies

Introducing Vipremett™, a novel treatment protocol for the treatment of KRAS+ colorectal, and pancreatic cancers.

Pharmaceutical treatment  of KRAS-mutant cancers has proven elusive.  Vipremett™ is a novel combination of drugs that is effective against cancers that exhibit a KRAS mutation. 

A provisional patent application has been filed to protect any formulation and mode of delivery of Vipremett™.

For more information on Vipremett™ and how it can be incorporated into your practice or for out-licensing opportunities please contact us.